Kanghua Biotech (300841.SZ) announced the signing of a recombinant hexavalent norovirus vaccine with HillEvax...
Zhitong Finance App News, Kanghua Biotech (300841.SZ) announced that regarding the progress of signing a license agreement with HillEvax for the recombinant six-valent norovirus vaccine, the company received a down payment of 15 million US dollars from HillEvax on March 26, 2024, of which the net amount was 13.5 million US dollars and HillEvax withheld income tax of 1.5 million US dollars.